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ABSTRACT 4 
Introduction: Patients with periprosthetic joint infection (PJI) undergoing two-stage exchange 5 
arthroplasty may undergo an interim spacer exchange for a variety of reasons including 6 
mechanical failure of spacer or persistence of infection. The objective of this study was to 7 
understand the risk factors and outcomes of patients that undergo spacer exchange during the 8 
course of a planned two-stage exchange arthroplasty. 9 
Methods: Our institutional database was used to identify 533 patients who underwent a two-stage 10 
exchange arthroplasty for PJI, including 90 patients with a spacer exchange, from 2000-2017. A 11 
retrospective review was performed to extract relevant clinical information. Treatment outcomes 12 
included 1) progression to reimplantation and 2) treatment success as defined by a Delphi-based 13 
criterion. Both univariate and multivariate COX regression models were performed to investigate 14 
whether spacer exchange was associated with failure. Additionally, a propensity score analysis 15 
was performed based on a 1:2 match. 16 
Results: A spacer exchange was required in 16.9%. Patients who underwent spacer exchanges 17 
had a higher body mass index (BMI) (p<0.001), rheumatoid arthritis (p=0.018), and were more 18 
likely to have PJI caused by resistant (0.048) and polymicrobial organisms (p=0.007). Patients 19 
undergoing a spacer exchange demonstrated lower survivorship and an increased risk of failure 20 
in the multivariate and propensity score matched analysis compared to patients who did not 21 
require a spacer exchange. 22 
Discussion: Despite an additional load of local antibiotics and repeat debridement, patients who 23 
underwent a spacer exchange demonstrated poor outcomes, including failure to undergo 24 
reimplantation and twice the failure rate. The findings of this study may need to be borne in mind 25 
when managing patients who require spacer exchange.  26 
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INTRODUCTION 30 
Treatment of periprosthetic joint infection (PJI) after total joint arthroplasty (PJI) remains 31 
a challenge with a high failure rate[1,2]. Two-stage exchange arthroplasty is the most frequent 32 
treatment for chronic PJI, involving removal of the components and insertion of an antibiotic 33 
impregnated cement spacer in the first stage and reimplantation of permanent implants at a later 34 
stage [3,4]. Outcomes after two stage exchange arthroplasty remain far from perfect as many 35 
patients are not ultimately reimplanted and multiple surgeries are frequently required to eradicate 36 
infection[2,5,6]. 37 
There are occasions when the initial antibiotic cement spacer may be exchanged, which is 38 
termed by some as the “three stage exchange” as it involves an additional surgical procedure. 39 
Reasons for a spacer exchange may include persistent infection or a fractured or dislocated 40 
spacer [2,7,8]. In patients with persistent infection, the rationale behind a spacer exchange is to 41 
deliver an additional load of local antibiotics and to repeat surgical debridement to treat the 42 
persistent infection.[9–11] Although this practice has been adopted by some surgeons, there is 43 
minimal literature on the outcomes of spacer exchange. Understanding the outcomes of spacer 44 
exchanges is important as a spacer exchange further delays reimplantation and subjects the 45 
patient to an additional surgery and all the morbidities associated with it.  46 
The aim of this study was to report the prevalence, characteristics and outcomes of 47 
patients with PJI who required a spacer exchange during the course of their intended two-stage 48 
exchange arthroplasty. We also intended to compare the outcome of these patients with those 49 
undergoing conventional two-stage revision without an interim spacer exchange.   50 
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MATERIALS AND METHODS 51 
A retrospective institutional study was performed to identify all patients with PJI who 52 
underwent a two-stage exchange arthroplasty from January 2000 to May 2017. The diagnosis of 53 
PJI was based on the Musculoskeletal Infection Society (MSIS) and the International Consensus 54 
Meeting criteria[12,13]. Patients with a megaprosthesis, initial infection with a fungal organism, 55 
prior native septic arthritis, or prior failed two-stage exchange arthroplasty were excluded.  We 56 
also excluded 80 patients with reimplantation due to follow-up less than 1 year after 57 
reimplantation and 18 patients without eventual reimplantation by May 2018 due to lost to 58 
follow-up after the last spacer insertion. After the aforementioned criteria, 533 joints (203 hips 59 
and 330 knees) were included in the final analysis. Of these 533 joints, 90 patients (31 hips and 60 
59 knees) underwent an initial interim spacer exchange during the course of their two-stage 61 
revision treatment (exchange group). This cohort was compared with a control group of 443 PJIs 62 
(172 hips and 271 knees) that did not undergo an interim spacer exchange (Figure 1).  63 
A retrospective review was performed to extract relevant information regarding surgical 64 
treatment, microbiology during resection arthroplasty, demographic data (age, body mass index 65 
[BMI], gender), Charlson comorbidity index (CCI) [15], diabetes, rheumatoid arthritis, index 66 
surgery (primary or revision), prior irrigation and debridement (I&D)  on the same joint, the 67 
presence of a sinus tract, follow-up time, date of surgery, and antibiotics used in the spacer. Both 68 
static (66.8%) and articulating spacers (33.2%) were utilized containing dual antibiotics against 69 
both gram positive and gram-negative organisms; 1 to 3 g of vancomycin and 1 to 3.6 g of 70 
tobramycin per 40-gram pack of bone cement was used almost exclusively (98.3%). The 71 
articulating spacers were intraoperatively constructed primarily from prefabricated molds with 72 
endoskeleton implants. The decision to undergo reimplantation was based on trending of serum 73 
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inflammatory markers and a healing wound. Routine aspiration prior to reimplantation was not 74 
performed. In patients in whom there was suspicion of continued infection, such as poor wound 75 
healing, intraoperative purulence, or mechanical spacer issues, it was institutional protocol for a 76 
repeat spacer to be performed in order to introduce a new load of antibiotics. The decision to 77 
perform multiple spacers exchanges rather than undergo salvage surgery with a girdlestone, or 78 
fusion was based on a shared decision between the patient and surgeon. Following 79 
reimplantation, patients were routinely suppressed with antibiotics starting in 2016. 80 
The primary endpoints of this study were 1) failure to ultimately undergo reimplantation, and 2) 81 
treatment failure after reimplantation as assessed by the Delphi method-based criteria by Diaz-82 
Ledezma [7]. The latter endpoint was defined as: 1) failed infection eradication, characterized by 83 
the presence of a sinus tract, drainage, pain, or infection recurrence caused by the same organism 84 
strain; 2) subsequent surgical intervention for infection after reimplantation surgery; or 3) 85 
occurrence of PJI-related mortality[16]. Patients on suppression were not considered a failure. 86 
Failure was only evaluated after reimplantation to ensure that the starting point was the same for 87 
both groups and to comply with the aforementioned definition of success. 88 
Statistical Analysis 89 
All of the statistical analyses were performed with the statistical software package R 90 
(http://www.R-project.org, The R Foundation). The clinical characteristics between groups were 91 
compared with the use of the independent t-test or Mann-Whitney test for continuous variables 92 
and the chi-square test or Fisher’s exact test for categorical variables. Kaplan-Meier survivorship 93 
curves were generated to compare outcomes and a log-rank test was performed to assess 94 
statistical significance. Both univariate and multivariate logistic regression models were 95 
performed to investigate whether spacer exchange was associated with failure to reimplantation 96 
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and Cox regression models were conducted to identify the relationship between spacer exchange 97 
and treatment failure. In the multivariate model, we adjusted all variables included in Table 1. 98 
Results were presented as odds ratios (OR) or hazards ratio (HR) with 95% confidence intervals 99 
(CI).   100 
Sensitivity Analysis 101 
A set of sensitivity analysis was performed using propensity score matching (PSM), 102 
which can adjust for some baseline group differences and is a well-accepted method to account 103 
for identified confounding variables [17,18]. Propensity scores of spacer exchange (vs. no spacer 104 
exchange) were estimated by logistic regression using age, gender, BMI, joints, CCI score, index 105 
surgery, diabetes, rheumatoid arthritis, the present of a sinus tract, prior I&D on the same joint, 106 
resistant organisms (Methicillin Resistant Staphylococcus Aureus (MRSA) or Vancomycin 107 
Resistant Enterococcus (VRE)), polymicrobial organisms, and duration of follow-up. Patients 108 
who underwent a spacer exchange were matched 1:2 (without a spacer exchange) on the logit of 109 
the propensity score using a nearest-neighbor matching approach. The maximum difference 110 
between propensity probabilities for matching was set at 0.2. A standardized mean difference 111 
(SMD) for each covariate was used to examine the balance of covariates between patients who 112 
received a spacer exchange and matched control individuals. PSM score was adjusted in the 113 
multivariate model. For all statistical analyses, significance was set at an alpha of 0.05. 114 
 115 
RESULTS 116 
Patient demographics and culture results at the initial spacer implantation are shown in 117 
Table 1. One or more spacer exchanges were required in 16.9% of two stage exchange 118 
arthroplasties (90/533). Patients in the spacer exchange group had a higher mean body mass 119 
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index (BMI) (34.4 ± 8.5 vs. 31.4 ± 8.0 kg/m^2, p<0.001) and percentage of rheumatoid arthritis 120 
(14.6% vs. 7.0%, p=0.018) compared to the control group. S. aureus was the predominant 121 
organism in both the spacer exchange and the control group (36.7% vs. 39.3%, p=0.643). The 122 
prevalence of PJI caused by resistant organisms (23.3% vs. 14.9%, p=0.048) and polymicrobial 123 
organisms (18.9% vs. 9.3%, p=0.007) were significantly higher in the spacer exchange group 124 
compared to controls. Of the patients with persistent infection, the organism was same between 125 
the spacer exchange and initial spacer insertion in 11.5% of patients, all of which were antibiotic 126 
resistant organisms (MRSA or VRE). 127 
Seventy-nine patients had only 1 spacer exchange (2 spacers total), 8 patients had 2 128 
spacer exchanges (3 spacers total), 2 patients had 3 spacer exchanges (4 spacers total), and 1 129 
patient had 4 spacer exchange (5 spacers total). The reasons for the initial spacer exchange 130 
included suspected persistence of infection (74/90), spacer dislocation (7/90), and fracture or 131 
unknown reasons (9/90). 132 
Of the 533 intended two stage exchange arthroplasties, the overall reimplantation rate 133 
was 79.7% (425/533). The reimplantation rate was 70.0% (63/90) for patients with at least one 134 
spacer exchange compared to 81.7% (362/443) for those without spacer exchange. After 135 
adjusting all confounders, patients with a spacer exchange were at an increased risk of failure to 136 
undergo reimplantation (OR, 1.96; 95% CI, 1.08 to 3.53; Table 2). The reasons for not 137 
undergoing reimplantation among 27 patients in the spacer exchange group were: medically unfit 138 
for reimplantation (n=11), salvage procedures for persistent infection (5 fusion, 3 amputation and 139 
1 girdlestone), death during stages (n=3), and decision to retain spacer either by the patient or the 140 
surgeon (n=4). 141 
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Following reimplantation, the overall treatment success rate according to the Delphia-142 
based definition was 75.1% (319/425) with a mean follow-up of 5.1 year (range 1.0 to 16.2 143 
years). The reinfection rate was 41.3% (26/63) for patients with spacer exchange compared to 144 
22.1% (80/362) for those without spacer exchange. In patients with a spacer exchange for 145 
mechanical failure, the failure rate after reimplantation was 33.33% (4/12) compared to 43.14% 146 
(22/51) in patients who underwent an exchange for infection (p = 0.746) and 22.10% (80/362) in 147 
those without a reoperation (p=0.479). After adjusting all confounders, the reinfection rate in 148 
patients with spacer exchange was significantly higher than controls (HR, 2.05; 95% CI, 1.08 to 149 
3.89; Table 3). Kaplan-Meier survivorship curves also revealed a significantly lower treatment 150 
success in the spacer-exchange group compared to controls using log-rank test (p<0.001, Figure 151 
2). The results were similar when isolating only patients that received a spacer exchange for 152 
infection; Kaplan-Meier survivorship curve revealed significantly lower treatment success rates 153 
in this stratified cohort as compared to controls (p<0.001, Figure 3). When stratified by joint, 154 
survivorship was lower in patients with a spacer exchange compared to those without a spacer 155 
exchange with treatment failure as an endpoint for both THAs (Figure 4) and TKAs (Figure 5). 156 
Through using propensity score matching (PSM), we generated a subsample of 88 cases 157 
with a spacer exchange and 176 matched controls without a spacer exchange. The patient 158 
characteristics after matching were shown in Appendix Table 1 and the quality of PSM was 159 
considered balanced (all SMD< 0.2). Patients with a spacer exchange did not demonstrate a 160 
higher rate of failure to undergo reimplantation in the propensity score analysis (PSM score-161 
adjusted OR, 1.44; 95% CI, 0.80 to 2.60; Table 2). The relationship between spacer exchange 162 
and subsequent reinfection remained robust; reinfection rate in patients with spacer exchange 163 
was significantly higher than matched controls (PSM score-adjusted HR, 2.23; 95% CI, 1.14 to 164 
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4.40; Table 3).  Kaplan-Meier survivorship curves revealed a significantly lower treatment 165 
success in the spacer-exchange group compared to matched controls (p=0.007, Appendix Figure 166 
1). When isolating only patients that received a spacer exchange for infection, the results did not 167 
change (p=0.006, Appendix Figure 2). 168 
 169 
DISCUSSION 170 
A spacer exchange for persistent infection or spacer-related mechanical complications 171 
such as fracture or dislocation may be performed in patients undergoing two-stage exchange 172 
arthroplasty. In the current study, 16.9% of patients who underwent an intended two-stage 173 
exchange arthroplasty had an interim spacer exchange. The primary reason of spacer exchange 174 
was suspicion of persistent infection. These patients were more likely to have obesity, 175 
rheumatoid arthritis, or PJI caused by resistant and/or polymicrobial organisms compared to 176 
those without a spacer exchange. Interestingly, spacer exchange was associated with an increased 177 
risk of reinfection following reimplantation regardless of whether the exchange was done for 178 
mechanical failure of the spacer or suspicion for persistence of infection. These findings 179 
continued to be present after the propensity score analysis which matched for baseline 180 
differences in comorbidities.  181 
To our knowledge, only one other study has specifically investigated outcomes after 182 
spacer exchanges[10]. In a series of 347 two stage exchanges, including 59 spacer exchanges, 183 
George et al. found that patients who underwent spacer exchanges had decreased survivorship 184 
(p=0.020) after reimplantation[10]. In addition, the spacer exchange group demonstrated 185 
increased comorbidities, and an increased prevalence of resistance organisms. Our results are 186 
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consistent with the prior study in demonstrating a poor outcome for patients undergoing an 187 
interim spacer exchange. 188 
There are several possibilities that may explain the poor outcome in patients with a spacer 189 
exchange. The most likely reason is that the patients may be poor hosts with increased 190 
comorbidities and/or difficult to eradicate organisms (e.g. resistant or polymicrobial) which may 191 
predispose the patient to persistent infection[19–21]. However, even in the multivariate and 192 
propensity score analysis, patients who underwent a spacer exchange, including those for 193 
mechanical failure of spacer, were more likely to have subsequent treatment failure. Thus, it is 194 
possible that the increased risk of treatment failure in patients undergoing spacer exchange may 195 
be the result of catabolic burden and morbidity that an additional surgery carries. This may be 196 
particularly true in patients with extensive comorbidities. In fact recognizing the issues related to 197 
an additional surgery, the Second International Consensus Meeting on Orthopedic Infections 198 
(ICM) recommends that patients with mechanical failure of a spacer should not undergo an 199 
additional spacer exchange unless the failed spacer results in soft tissue problems[11]. 200 
Regardless of the reason for the increased risk of failure and poor outcome, the present study 201 
suggests that the frequent treatment of a persistent infection after a two-stage exchange with an 202 
additional repeat spacer demonstrates poor outcomes and that the utility of this treatment method 203 
should be reconsidered.  204 
Another important issue to examine is that patients who failed after a two-stage exchange 205 
arthroplasty or were suspected of having a persistent infection are more likely to be infected with 206 
more virulent organisms such as Staphylococcal species and/or resistant organisms [5,22,23,24], 207 
We found similar results in this study, with Staphylococcal species comprising the majority of 208 
persistent infections during the first spacer exchange followed closely by other resistant 209 
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organisms. While subsequent surgery after failure of a two-stage exchange demonstrate poor 210 
outcomes in the literature, we found that patients undergoing spacer exchanges mirror these 211 
results with a high rate of salvage procedures. 212 
There are several limitations to this study that should be considered. First, the study is 213 
retrospective in nature and thus relies on accurate and detailed documentation. This limitation is 214 
particularly important when evaluating the reason for not undergoing reimplantation, as this was 215 
infrequently recorded in the medical record.  In addition, although clinical signs and 216 
improvement are also used as a proxy for infection control, this information is difficult to obtain 217 
in a retrospective study. Furthermore, there were differences in baseline characteristics which 218 
may result from a selection bias as it is feasible that a surgeon is more aggressive and more likely 219 
to perform a spacer exchange in patients with increased comorbidities and/or PJI caused by 220 
resistant organisms. However, we attempted to control for these baseline differences using both a 221 
multivariate analysis and propensity score matching based analysis. In addition, the influence of 222 
antibiotic suppression could not be controlled for as this information was not readily available. 223 
Furthermore, while we found that patients that underwent a spacer exchange were more likely to 224 
have rheumatoid arthritis, we were unable to investigate the influence of anti-rheumatic 225 
medication, including the role of modern disease-modifying antirheumatic drugs, which 226 
selectively target the immune system. Additionally, many patients were lost to follow up as 227 
many of these patients were referred from an outside hospital and follow-up with their original 228 
surgeon whose records are not readily available. This may thus reflect an underestimation of the 229 
true failure rate. Lastly, it was routine protocol to perform a spacer exchange rather than a 230 
girdlestone at our institution with the intent of introducing more local antibiotics. We 231 
acknowledge that there is no clear consensus regarding the optimal management of persistent 232 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
infection in the setting of a spacer and that some surgeons will resort to an “implant holiday” 233 
prior to an intended reimplantation.  234 
In summary, the present study highlights the challenges that remain in managing patients 235 
with persistent infection after an initial spacer implantation. Despite delivery of an additional 236 
load of local antibiotics and further debridement, outcome of surgical treatment of these patients 237 
remains poor and the risk of failure is actually increased. Furthermore, a significant number of 238 
patients with a spacer exchange never ultimately undergo reimplantation despite being subject to 239 
the morbidity of another surgery. Surgeons should be cognizant of these suboptimal outcomes 240 
after treatment with an additional spacer exchange and alternative strategies are certainly needed. 241 
It is crucial for subsequent studies to understand risk factors for subsequent failure of a spacer 242 
exchange in order to determine the indications for a spacer exchange.  243 
  244 
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Appendix Table 1 Patient demographics after matching 
 
 
 
Exchange 
group 
(N=88) 
Non-exchange group 
(N=176) SMD P-value  
Age (year) (mean ± SD) 65.6 ± 10.3 66.4 ± 10.7 0.0777 0.555  
Male (%) 43 (48.9) 97 (55.1%) 0.1253 0.407  
BMI (kg/m2) 34.4 ± 8.5 32.9 ± 8.9 0.1712 0.195  
Hip (%) 31 (35.2) 68 (38.6) 0.0707 0.686  
CCI score (mean ± SD) 3.9 ± 1.72 4.1 ± 1.9 0.1545 0.247  
Diabetes (%) 27 (30.7) 58 (33) 0.0488 0.816  
Rheumatoid arthritis (%) 13 (14.8) 21 (11.9) 0.0836 0.649  
Index revision (%) 30 (34.1) 56 (31.8) 0.0484 0.816  
Prior I&D (%) 24 (27.3) 53 (30.1) 0.0628 0.738  
Sinus tract (%) 25 (28.4) 56 (31.8) 0.0744 0.671  
Resistant organism (%) 21 (23.9) 40 (22.7) 0.0269 0.959  
Polymicrobial (%) 16 (18.2) 31 (17.6) 0.0148 1.000  
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Table 1 Patient demographics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Coagulase negative staphylococcus 
 
 
 
Exchange group 
(N=90) 
Non-exchange 
group 
(N=443) 
P-value 
Age (year) (mean ± SD) 65.5 ± 10.2 66.0 ± 11.4 0.364 
Male (n, %) 44 (49.4%) 222 (51.7%) 0.692 
BMI (kg/m2) 34.4 ± 8.5 31.4 ± 8.0 <0.001 
Hip (n, %) 31 (34.4%) 172 (38.8%) 0.435 
CCI score (mean ± SD) 3.9 ± 1.7 3.8 ± 1.8 0.842 
Diabetes (n, %) 27 (30.0%) 101 (22.8%) 0.145 
Rheumatoid arthritis (n, %) 13 (14.6%) 30 (7.0%) 0.018 
Index revision (n, %) 30 (33.3%) 108 (24.4%) 0.077 
Prior I&D (n, %) 26 (28.9%) 146 (33.0%) 0.452 
Sinus tract (n, %) 25 (28.1%) 99 (22.3%) 0.242 
Culture at resection arthroplasty (n, %) 
S. aureus 33 (36.7%) 174 (39.3%) 0.643 
CNS* 26 (28.9%) 95 (21.4%) 0.124 
Resistant organism  21 (23.3%) 66 (14.9%) 0.048 
Streptococcus spp. 10 (11.1%) 55 (12.4%) 0.730 
Enterococcus spp. 8 (8.9%) 20 (4.5%) 0.115 
Gram-negative organism 14 (15.6%) 51 (11.5%) 0.285 
Polymicrobial organism 17 (18.9%) 41 (9.3%) 0.007 
Culture negative 10 (11.1%) 71 (16.0%) 0.236                    
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Table 2 Univariate and multivariate analysis for failure to undergo reimplantation  
* Before matching, all confounders in Table 1 were adjusted; after matching, PSM score were 
adjusted. 
 
 
Reimplantation 
(n, %) P-value 
Non-adjusted 
OR P-value *Adjust OR P-value 
Before matching       
Non-exchange 
group 362 (81.7%) - Reference - Reference - 
Exchange group 63 (70.0%) 0.012 1.92 (1.15, 3.19) 0.013 1.96 (1.08, 3.53) 0.026  
After matching       
Non-exchange 
group 135 (76.7%) - Reference - Reference - 
Exchange group 61 (69.3%) 0.196 1.46 (0.82, 2.58) 0.197 1.44 (0.80, 2.60) 0.220 
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Table 3 Univariate and multivariate analysis for association between spacer exchange and 
treatment failure 
* Before matching, all confounders in Table 1 were adjusted; after matching, PSM score were 
adjusted. 
 
 
Failure 
(n, %) P-value 
Non-adjusted 
HR P-value *Adjust HR P-value 
Before matching       
Non-exchange 
group 80 (22.1%) - Reference - Reference - 
Exchange group 26 (41.3%) 0.001 2.48 (1.42, 4.34) 0.002 2.05 (1.08, 3.89)   0.028   
After matching       
Non-exchange 
group 31 (23.0%) - Reference - Reference - 
Exchange group 24 (39.3%) 0.018 2.18 (1.13, 4.18) 0.019 2.23 (1.14, 4.40) 0.020 
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Figure Legend 
 
Figure 1 Study flowchart  
Figure 2 Kaplan-Meier survivorship curve for entire cohort versus controls with treatment 
failure as an endpoint. 
Figure 3 Kaplan-Meier survivorship curve for subgroup of cohort who underwent spacer 
exchange only for infection (i.e. not for dislocation or other non-infection reasons) versus all 
controls with treatment failure as an endpoint 
Figure 4 Kaplan-Meier survivorship curve for entire cohort versus controls for two-stage 
exchange arthroplasty after THA PJI with treatment failure as an endpoint 
Figure 5 Kaplan-Meier survivorship curve for entire cohort versus controls for two-stage 
exchange arthroplasty after THA PJI with treatment failure as an endpoint 
Appendix Figure 1 Kaplan-Meier implant survivorship curve for entire cohort versus controls 
after matching 
Appendix Figure 2 Kaplan-Meier implant survivorship curve for subgroup of cohort who 
underwent spacer exchange only for infection (i.e. not for dislocation or other non-infection 
reasons) versus controls after matching 
 
